Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Nikki Glaser has been testing out Golden Globes jokes. There's one nobody wants to hear - 2Step by step instructions to Appropriately Keep up with Your Sunlight powered chargers for Most extreme Productivity
- 3Astounding Treehouses All over the Planet
- 4German men need approval for stays abroad under military service law
- 5The most effective method to Refresh the Infotainment Framework in the Volvo XC40
- Instructions to Utilize Your Brain science Certification to Work on Corporate Culture
- Pacific voyagers’ remarkable environmental knowledge allowed for long-distance navigation without Western technology
- Ukrainian man arrested in Germany on suspicion of spying for Russia
- Investigating Remarkable Espresso Flavors: Upgrade Your Day to day Blend
- Make your choice for the bird that catches your heart!
- German gas price bill signed into law, but consumers not impressed
- They relied on marijuana to get through the day. But then days felt impossible without it
- Cocaine, caffeine, painkillers consumed by sharks in Bahamas, study finds
- Insight: Pills, TikTok, weight-loss apps and the consumer-driven future of GLP-1s
